Home › Companies › Zentalis Pharmaceuticals, Inc. › 2025-2026
At Zentalis Pharmaceuticals, Inc.'s shareholder meeting held June 16, 2026, in the 2025-2026 proxy season, 75 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 254 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED… — Zentalis Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 67% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Zentalis Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Zentalis Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 16, 2026: 4 items on Zentalis Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026: 1 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Zentalis Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Zentalis Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David Johnson | 20,711,869 | -- | -- | 12,215,784 | 16,526,113 | 63% | Not verified | — |
| Elect Director: Jan Skvarka, Ph.D. | 23,497,184 | -- | -- | 9,430,469 | 16,526,113 | 71% | Not verified | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 49,321,951 | 13,557 | 118,258 | -- | 0 | 99.9% | Not verified | — |
| 3. Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers | 21,949,844 | 10,930,673 | 47,136 | -- | 16,526,113 | 67% | Approved | — |
Source: Zentalis Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
Each item below shows how the 75 asset managers that disclosed a Zentalis Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: Election of each of the Class III Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: David Johnson
Zentalis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David Johnson”): 20,711,869 for, 12,215,784 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 3,439,433 for, 1,012,609 withheld, 179,739 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,663,675 | 0 | 44 | 7,181 | For |
| PRIMECAP Odyssey Funds | 676,400 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 440,039 | Withhold |
| Fidelity | 0 | 0 | 0 | 269,179 | Withhold |
| BlackRock | 0 | 0 | 163,002 | 0 | Abstain |
| Dimensional | 0 | 0 | 0 | 81,063 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 77,300 | Withhold |
| Federated Hermes | 59,775 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 52,942 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 50,000 | Withhold |
| Goldman Sachs | 32,271 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 15,600 | Withhold |
| Jackson National | 0 | 0 | 13,398 | 0 | Abstain |
| Equitable | 0 | 0 | 0 | 11,113 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 7,312 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 6,070 | Withhold |
| Allianz | 0 | 0 | 2,020 | 0 | Abstain |
| Invesco | 0 | 0 | 0 | 1,333 | Withhold |
| John Hancock | 0 | 0 | 1,275 | 0 | Abstain |
| Guggenheim | 0 | 0 | 0 | 428 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 361 | Withhold |
Combines 4 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Description as filed by funds: Election of each of the Class III Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Jan Skvarka, Ph.D.
Zentalis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jan Skvarka, Ph.D.”): 23,497,184 for, 9,430,469 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 4,274,745 for, 332,994 withheld, 24,042 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,666,056 | 0 | 37 | 4,807 | For |
| PRIMECAP Odyssey Funds | 676,400 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 440,039 | 0 | 0 | 0 | For |
| Fidelity | 207,027 | 0 | 0 | 62,152 | Mixed |
| BlackRock | 163,002 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 81,063 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 77,300 | Withhold |
| Federated Hermes | 59,775 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 52,942 | Withhold |
| Charles Schwab | 50,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 32,271 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 15,600 | Withhold |
| Jackson National | 0 | 0 | 13,398 | 0 | Abstain |
| Equitable | 11,113 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 7,312 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 0 | 6,070 | Withhold |
| Allianz | 0 | 0 | 2,020 | 0 | Abstain |
| Invesco | 1,333 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 1,275 | 0 | Abstain |
| Guggenheim | 0 | 0 | 0 | 428 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 361 | Withhold |
Combines 3 wordings of this item as funds reported it.
67% Approved · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Zentalis Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers”): 21,949,844 for, 10,930,673 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,668,484 | 2,417 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 676,400 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 440,039 | 0 | 0 | Against |
| Fidelity | 0 | 269,179 | 0 | 0 | Against |
| BlackRock | 163,002 | 0 | 0 | 0 | For |
| Dimensional | 0 | 81,063 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 77,300 | 0 | 0 | Against |
| Federated Hermes | 59,775 | 0 | 0 | 0 | For |
| American Century | 0 | 52,942 | 0 | 0 | Against |
| Charles Schwab | 0 | 50,000 | 0 | 0 | Against |
| Goldman Sachs | 32,271 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 15,600 | 0 | 0 | Against |
| Jackson National | 0 | 13,398 | 0 | 0 | Against |
| Equitable | 11,113 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 0 | 7,312 | 0 | 0 | Against |
| Lincoln Financial | 0 | 6,070 | 0 | 0 | Against |
| Allianz | 0 | 2,020 | 0 | 0 | Against |
| Invesco | 0 | 1,333 | 0 | 0 | Against |
| John Hancock | 0 | 1,275 | 0 | 0 | Against |
| Guggenheim | 0 | 428 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 361 | 0 | 0 | Against |
Fund voting reports, all 21 managers: 3,611,045 for, 1,020,737 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 3,947,913 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 2,302,449 | 0 | 0 | Against |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 1,728,879 | 0 | 0 | Against |
| Citadel | 1,559,448 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 1,323,327 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 0 | 1,199,364 | 0 | 0 | Against |
| DE Shaw | 0 | 1,127,908 | 0 | 0 | Against |
| Renaissance | 0 | 956,184 | 0 | 0 | Against |
| PFIZER INC | 953,834 | 0 | 0 | 0 | For |
| BlackRock | 916,519 | 32,627 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 938,320 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 441,000 | 0 | 0 | 0 | For |
| Vanguard | 335,896 | 6,371 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 333,550 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 325,236 | 0 | 0 | Against |
| Soleus Capital Management, L.P. | 302,519 | 0 | 0 | 0 | For |
| Woodline Partners LP | 266,032 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 252,997 | 0 | 0 | Against |
| Stonepine Capital Management, LLC | 245,500 | 0 | 0 | 0 | For |
| State Street | 214,767 | 481 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 0 | 125,745 | 0 | 0 | Against |
| Peapod Lane Capital LLC | 103,551 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 0 | 102,448 | 0 | 0 | Against |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 77,300 | 0 | 0 | Against |
| Federated Hermes | 72,762 | 0 | 0 | 0 | For |
Institutional-manager reports, all 62 managers: 11,673,883 for, 9,090,285 against. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Zentalis Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 49,321,951 for, 13,557 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 4,631,781 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,670,900 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 676,400 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 440,039 | 0 | 0 | 0 | For |
| Fidelity | 269,179 | 0 | 0 | 0 | For |
| BlackRock | 163,002 | 0 | 0 | 0 | For |
| Dimensional | 81,063 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 77,300 | 0 | 0 | 0 | For |
| Federated Hermes | 59,775 | 0 | 0 | 0 | For |
| American Century | 52,942 | 0 | 0 | 0 | For |
| Charles Schwab | 50,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 32,271 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 15,600 | 0 | 0 | 0 | For |
| Jackson National | 13,398 | 0 | 0 | 0 | For |
| Equitable | 11,113 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 7,312 | 0 | 0 | 0 | For |
| Lincoln Financial | 6,070 | 0 | 0 | 0 | For |
| Allianz | 2,020 | 0 | 0 | 0 | For |
| Invesco | 1,333 | 0 | 0 | 0 | For |
| John Hancock | 1,275 | 0 | 0 | 0 | For |
| Guggenheim | 428 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 361 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,186,348 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.75% |
| 2 | PRIMECAP Odyssey Funds | 0.95% |
| 3 | FRANKLIN STRATEGIC SERIES | 0.62% |
| 4 | Fidelity | 0.38% |
| 5 | BlackRock | 0.23% |
| 6 | Dimensional | 0.11% |
| 7 | BRIDGEWAY FUNDS INC | 0.11% |
| 8 | Federated Hermes | 0.08% |
| 9 | American Century | 0.07% |
| 10 | Charles Schwab | 0.07% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | 5AM Venture Management, LLC | 5.55% |
| 2 | Two Sigma | 3.23% |
| 3 | ACADIAN ASSET MANAGEMENT LLC | 2.43% |
| 4 | Citadel | 2.19% |
| 5 | Decheng Capital LLC | 1.86% |
| 6 | FRANKLIN ADVISERS INC | 1.68% |
| 7 | DE Shaw | 1.58% |
| 8 | Renaissance | 1.34% |
| 9 | PFIZER INC | 1.34% |
| 10 | BlackRock | 1.33% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| WALTERS GROUP | 25.07% | 13G |
| Entities affiliated with The Walters Group | 18.98% | DEF14A |
| Entities affiliated with 5AM Ventures | 6.80% | DEF14A |
| Entities affiliated with Squadron Capital | 5.17% | DEF14A |
| Squadron Master Fund LP | 5.17% | 13G |
| Two Sigma | 4.15% | 13F |
| Vanguard Group | 4.01% | 13F |
| Barclays PLC | 3.18% | 13G |
| Renaissance Technologies | 2.72% | 13F |
| Citadel Advisors | 2.47% | 13F |
Percentages above are of 71,186,348 shares outstanding, as reported by Zentalis Pharmaceuticals, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Zentalis Pharmaceuticals, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Zentalis Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Zentalis Pharmaceuticals (ZNTL) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/zentalis-pharmaceuticals-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.